EUVIMEDEUVIMED entdecken
Open Access

Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma

Arularasan Anbinselvam, Abdul-Warith O Akinshipo iD, Akinyele O Adisa iD, Olajumoke A Effiom iD, Xinhe Zhu, Kehinde E Adebiyi iD, Godwin T Arotiba iD, Sunday O Akintoye iD

Journal of Oral Pathology & Medicine · 2024

DOI: 10.1111/jop.13506 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oral Pathology & Medicine, 2024. Verfasst von Arularasan Anbinselvam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ameloblastoma, Odontogenic Tumors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ameloblastoma is an aggressively growing, highly recurrent odontogenic jaw tumor. Its association with BRAFV600E mutation is an indication for BRAFV00E‐inhibitor therapy The study objective was to identify a sensitive low‐cost test for BRAFV600E‐positive ameloblastoma. We hypothesized that immunohistochemical staining of formalin‐fixed paraffin‐embedded tissues for BRAFV600E mutation is a low‐cost surrogate for BRAFV600E gene sequencing when laboratory resources are inadequate for molecular testing.

Methods

Tissues from 40 ameloblastoma samples were retrieved from either formalin‐fixed paraffin‐embedded blocks, RNAlater™ stabilization solution or samples inadvertently pre‐fixed in formalin before transfer to RNAlater™. BRAFV600E mutation was assessed by Direct Sanger sequencing, Amplification Refractory Mutation System‐PCR and immunohistochemistry (IHC).

Results

BRAFV600E mutation was detected by IHC, Amplification Refractory Mutation System‐PCR and Direct Sanger sequencing in 93.33%, 52.5% and 30% of samples respectively. Considering Direct Sanger sequencing as standard BRAFV600E detection method, there was significant difference between the three detection methods (𝜒 2 (2) = 31.34, p < 0.0001). Sensitivity and specificity of IHC were 0.8 (95% CI: 0.64–0.90) and 0.9 (95% CI: 0.75–0.99) respectively, while positive predictive value and negative predictive value (NPV) were 0.9 and 0.8 (Fischer's test, p < 0.0001) respectively. Sensitivity and specificity of Amplification Refractory Mutation System‐PCR detection method were 0.7 (95% CI: 0.53–0.80) and 0.9 (95% CI = 0.67–0.98) respectively, while PPV and NPV were 0.9 and 0.6 respectively (Fischer's test, p < 0.0001).

Conclusion

Low‐cost and less vulnerability of IHC to tissue quality make it a viable surrogate test for BRAFV600E detection in ameloblastoma. Sequential dual IHC and molecular testing for BRAFV600E will reduce equivocal results that could exclude some patients from BRAFV600E‐inhibitor therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmeloblastomaOdontogenic TumorsHumansProto-Oncogene Proteins B-rafMutationFormaldehyde

Stichwörter der Autor:innen

BRAFameloblastomadiagnosticsrecurrencetargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafFormaldehyde

Autor:innen und Institutionen

  • Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Oral and Maxillofacial Pathology/Biology, Faculty of Dental Sciences, University of Lagos, Lagos, Nigeria.
  • Department of Oral Pathology, University of Ibadan and University College Hospital Ibadan, Ibadan, Nigeria.
  • Department of Oral Pathology & Oral Medicine, Faculty of Dentistry, Lagos State University College of Medicine Lagos, Lagos, Nigeria.
  • Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, University of Lagos, Lagos, Nigeria.

ORCID-Profile: Abdul-Warith O Akinshipo, Akinyele O Adisa, Olajumoke A Effiom, Kehinde E Adebiyi, Godwin T Arotiba, Sunday O Akintoye

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Anbinselvam, A., Akinshipo, A. O., Adisa, A. O., Effiom, O. A., Zhu, X., Adebiyi, K. E., Arotiba, G. T., & Akintoye, S. O. (2024). Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13506

Vancouver

Anbinselvam A, Akinshipo AO, Adisa AO, Effiom OA, Zhu X, Adebiyi KE, et al. Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma. Journal of Oral Pathology & Medicine. 2024. doi:10.1111/jop.13506

BibTeX
@article{Anbinselvam2024,
  author = {Anbinselvam, Arularasan and Akinshipo, Abdul-Warith O and Adisa, Akinyele O and Effiom, Olajumoke A and Zhu, Xinhe and Adebiyi, Kehinde E and Arotiba, Godwin T and Akintoye, Sunday O},
  title = {Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma},
  journal = {Journal of Oral Pathology & Medicine},
  year = {2024},
  doi = {10.1111/jop.13506}
}
Kostenlos starten →